Faran Shimi Pharmaceutical Company and Varian Pharmad participated in the 2024 Addiction Science Congress with the aim of playing an effective role in supporting scientific research, advancing knowledge, and providing effective treatment solutions in the field of addiction.
According to the public relations department of the Golrang Pharmaceutical Group, this event provided a valuable opportunity for interaction with specialists, researchers, and activists in this field, focusing on the exchange of knowledge and the exploration of innovative methods for the prevention and treatment of addiction.
During the three days of the congress, these two companies, with their prominent and active presence, not only presented their latest research achievements and innovative products but also supported new research in this field.
Scientific sessions, paper presentations, and discussions with experts and elites created a suitable platform for addressing challenges, exchanging experiences, and finding more effective solutions for the treatment and reduction of addiction-related harms.
Faran Shimi Pharmaceutical Company, with over 17 years of experience in producing drugs related to addiction treatment, manufactures and supplies products such as Opium Tincture (Opium Syrup), Methadone Syrup, Methadone Tablets, Sublingual Buprenorphine Tablets, and Buprenorphine-Naloxone Combination. These drugs are used as part of treatment programs for managing and reducing dependence on narcotics.
Additionally, Varian Pharmad has introduced a new product called “Buprenorphine Extended-Release 100/300 mg” to the market. This drug, known by the generic name “Buprenorphine,” falls under the category of pain relief and addiction treatment medications and is produced in injectable form. The launch of this product marks an important step in improving maintenance treatments and reducing dependence on narcotics.
